Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDX-101 + Chlorambucil in CLL
NCT00151736Phase 2Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Sep 2004
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of r-etodolac in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Cephalon, Inc. Primary endpoint: Bone Marrow Biopsy or Aspiration at 6 months. Started Sep 2004; status: terminated.
02
Drugs
r-etodolac
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00151736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151736.